Jaguar Health (JAGX) Net Cash Flow Growth (3y) (2017 - 2026)
Jaguar Health (JAGX) Net Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,774.59 Bn | 1,774.53 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 3 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | 38.47% |
| 4 | Vertex Pharmaceuticals | 123.91 Bn | 116.66 Bn | 2.59 Bn | 33.37% |
| 5 | Regeneron Pharmaceuticals | 71.79 Bn | 63.04 Bn | 3.31 Bn | -29.82% |
| 6 | Belite Bio | 62.15 Bn | 62.15 Bn | - | - |
| 7 | Argenx Se | 54.75 Bn | 49.57 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.10 Bn | 35.10 Bn | 959.66 Mn | 32.17% |
| 9 | Revolution Medicines | 36.11 Bn | 36.11 Bn | - | - |
| 10 | Jaguar Health | 509,443.80 | -9.55 Mn | 19.11 Mn | -37.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.02% |
| Dec 31, 2025 | 41.59% |
| Sep 30, 2025 | 0.17% |
| Jun 30, 2025 | 21.11% |
| Mar 31, 2025 | -92.74% |
| Dec 31, 2024 | -46.04% |
| Sep 30, 2024 | 47.60% |
| Jun 30, 2024 | 148.07% |
| Mar 31, 2024 | -39.99% |
| Dec 31, 2023 | -22.00% |
| Sep 30, 2023 | -47.82% |
| Jun 30, 2023 | -82.08% |
| Mar 31, 2023 | 80.58% |
| Dec 31, 2022 | -69.14% |
| Sep 30, 2022 | 50.74% |
| Jun 30, 2022 | -95.98% |
| Mar 31, 2022 | 384.53% |
| Dec 31, 2021 | 36.41% |
| Sep 30, 2021 | -126.32% |
| Jun 30, 2021 | 60.52% |